Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
Greater than 50 Percent Reduction in Patients Classified as Low Risk for Lung Cancer SAN FRANCISCO --(BUSINESS WIRE)-- Correcting quote attribution in the third paragraph of release issued Nov. 1, 2017 . The corrected release reads: VERACYTE ANNOUNCES PRESENTATION OF NEW CLINICAL UTILITY DATA AT
View HTML
Toggle Summary Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 9, 2017 at 3:00 p.m.
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on Monday, November 6, 2017
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its third quarter 2017 financial results after the close of market on Monday, November 6, 2017 . Following the announcement, Veracyte will host a conference call and webcast at 4:30
View HTML
Toggle Summary Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA
Next-Generation Test is First to Distinguish Benign from Cancerous Hürthle Cells; New Algorithms Identified MTC with 100 Percent Sensitivity and Specificity SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that data presented today at the 87 th Annual Meeting
View HTML
Toggle Summary Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that data presented at the 87 th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC , Canada demonstrate the accuracy of identification of BRAF V600E and
View HTML
Toggle Summary Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ:VCYT) today announced that data from a prospective clinical utility study demonstrating the ability of the Percepta ® Bronchial Genomic Classifier to safely reduce unnecessary invasive procedures in lung cancer screening and
View HTML
Toggle Summary Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting
- The Coulter Foundation's Wallace H. Coulter Award for Healthcare Innovation Recognizes Excellence and Leadership in Clinical Diagnostic Medicine - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc . (NASDAQ: VCYT) announced today that the company's Chairman and CEO Bonnie Anderson is
View HTML
Toggle Summary Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that data from five studies validating the performance of the next-generation Afirma ® Genomic Sequencing Classifier (GSC) in thyroid cancer diagnosis will be presented at the 87 th Annual Meeting of the
View HTML
Toggle Summary Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc . (NASDAQ: VCYT) today announced that the Centers for Medicare & Medicaid Services (CMS) published preliminary 2018 rates for clinical diagnostic laboratory tests. The reimbursement rate for the Afirma Genomic Classifier (code 81545) is
View HTML
Toggle Summary Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together
Veracyte, Inc. and the Lung Cancer Initiative Partner to Launch New Pilot Campaign in North Carolina
View HTML